WO1996003430A1 - Organic compounds - Google Patents
Organic compounds Download PDFInfo
- Publication number
- WO1996003430A1 WO1996003430A1 PCT/EP1995/002966 EP9502966W WO9603430A1 WO 1996003430 A1 WO1996003430 A1 WO 1996003430A1 EP 9502966 W EP9502966 W EP 9502966W WO 9603430 A1 WO9603430 A1 WO 9603430A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compounds
- leu
- substituted
- alkyl
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 197
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 67
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 238000002360 preparation method Methods 0.000 claims description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- -1 α-hydroxy-substituted butyric acid residue Chemical group 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 229940126062 Compound A Drugs 0.000 claims description 17
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 17
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 150000002431 hydrogen Chemical group 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 9
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical group C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000002538 fungal effect Effects 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 4
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 239000012038 nucleophile Substances 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- CLUOCCWZZAGLPM-UHFFFAOYSA-N diphenyl-sulfanyl-sulfanylidene-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(=S)(S)C1=CC=CC=C1 CLUOCCWZZAGLPM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000002148 esters Chemical group 0.000 claims description 3
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical group N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 2
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical group CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 claims description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical group CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000001212 derivatisation Methods 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229910052987 metal hydride Inorganic materials 0.000 claims description 2
- 150000004681 metal hydrides Chemical class 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 150000002902 organometallic compounds Chemical class 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000010561 standard procedure Methods 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 150000003463 sulfur Chemical class 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- VDCLCAXYTCLVQY-CTVGSUQISA-N 2-[(3s,6s,9s,15s,18s,21s,24s,27s)-15,18-di(butan-2-yl)-6-[(4-methoxyphenyl)methyl]-3,10,16,19,22,28-hexamethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-9,24,27-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.4.0]tetratriacontan-21-yl]acetic acid Chemical compound C([C@H]1C(=O)N[C@@H](C)C(=O)N2CCCCC2C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@H](C(=O)N(C)[C@@H](CC(O)=O)C(=O)N(C)[C@@H](C(C)CC)C(=O)N(C)[C@H](C(NCC(=O)N(C)[C@@H](C(C)C)C(=O)N1)=O)C(C)CC)C(C)C)C1=CC=C(OC)C=C1 VDCLCAXYTCLVQY-CTVGSUQISA-N 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 336
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 225
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 159
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 159
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 156
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 156
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 64
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 51
- 239000000741 silica gel Substances 0.000 description 49
- 229910002027 silica gel Inorganic materials 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 36
- 239000000126 substance Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 26
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 23
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 23
- 238000004587 chromatography analysis Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 17
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 17
- 239000006260 foam Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 102000015689 E-Selectin Human genes 0.000 description 11
- 108010024212 E-Selectin Proteins 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 229910052796 boron Inorganic materials 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000012267 brine Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000008259 solid foam Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000004276 hyalin Anatomy 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000351901 Bartalinia Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LIBASNWCFRYHQB-UHFFFAOYSA-N (2,3-dichlorophenyl)-diphenylphosphane Chemical compound ClC1=CC=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1Cl LIBASNWCFRYHQB-UHFFFAOYSA-N 0.000 description 1
- HBDJFVFTHLOSDW-DNDLZOGFSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;hydrate Chemical compound O.O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HBDJFVFTHLOSDW-DNDLZOGFSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical class CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- PTXVSDKCUJCCLC-UHFFFAOYSA-N 1-hydroxyindole Chemical compound C1=CC=C2N(O)C=CC2=C1 PTXVSDKCUJCCLC-UHFFFAOYSA-N 0.000 description 1
- RUGISKODRCWQNE-UHFFFAOYSA-N 2-(2-methylphenyl)ethanol Chemical compound CC1=CC=CC=C1CCO RUGISKODRCWQNE-UHFFFAOYSA-N 0.000 description 1
- APISVOVOJVZIBA-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC#N)C1=CC=CC=C1 APISVOVOJVZIBA-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 101001027553 Bos taurus Fibronectin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 0 C*C*C(C(*)*1*)c2c1cccc2 Chemical compound C*C*C(C(*)*1*)c2c1cccc2 0.000 description 1
- 101100095895 Drosophila melanogaster sle gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000006364 carbonyl oxy methylene group Chemical group [H]C([H])([*:2])OC([*:1])=O 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ASWXNYNXAOQCCD-UHFFFAOYSA-N dichloro(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Cl)(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 ASWXNYNXAOQCCD-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960003017 maltose monohydrate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Definitions
- This invention relates to cyclopeptolides and to their therapeutic use as inhibitors of adhesion molecule expression.
- Cellular adhesion molecules such as ICAM-1 , VCAM-1 and E-selectin are expressed on the surface of endothelial cells, as well as keratinocytes for ICAM-1 , in response to proinflammatory mediators including TNF ⁇ , IFN ⁇ , IL1 and LPS.
- Corresponding counterligands e.g. LFA-1 , VLA-4 and SLE*, are expressed on the surfaces of circulating blood cells.
- Transendotheiial migration of leucocytes during inflammatory processes, as well as extravascular cell-cell interactions are regulated as a result of the interactions between these adhesion molecules and their counterligands. Consequently, inhibitors of adhesion molecule expression offer potential for the treatment of many disease states. However, no suitable low molecular weight inhibitors of adhesion molecule expression are currently available.
- Cyclopeptolides are cyclic molecules comprising amino acid residues linked together by peptide bonds and at least one hydroxy substituted carboxylic acid residue which is linked through its hydroxyl substituent to the neighbouring acid residue by an ester linkage.
- the present invention provides cycloheptapeptolides of formula I
- A is an ⁇ -hydroxy-substituted butyric acid residue optionally ⁇ -substituted by R ⁇ , which represents CN, COOR 2 , CONR 3 R 4 , COR 5 , CSNH 2 or alkyl, which may be substituted by azido, halogen, alkoxy, optionally protected hydroxy or amino, vinyl, which may be substituted by alkyl, halogen or CN,- cycloalkyl, tetrazolyl or -C ⁇ CH, wherein R 2 represents hydrogen or optionally arylsubstituted alkyl, R 3 and R 4 are the same or different and represent hydrogen or alkyl or form together with the nitrogen a 3- to 6- membered ring optionally containing a second heteroatom, and R 5 represents hydrogen or lower alkyl,
- B is an ⁇ -amino- ⁇ -methyl-substituted octanoic acid residue
- R 1 is hydrogen or methyl
- C is a tryptophan or N-methyl-tryptophan residue of formula VI
- R 8 represents hydrogen, alkoxy, alkyl or benzyl
- R 9 represents hydrogen or halogen
- R 10 represents hydrogen or methyl and ---- represents a single or double bond
- X is an ⁇ -amino-substituted (C 2 to C 14 ) carboxylic acid residue
- Y is an ⁇ -amino- or N-methyl- ⁇ -amino substituted (C 2 to C 10 ) carboxylic acid residue.
- R 1 is methyl, the residues R 1 -Leu and Leu are N-methyl-leucine and leucine residues respectively.
- A is an ⁇ -hydroxy butyric acid residue, which is ⁇ -substituted by cyano, COOR 2 ', whererby R 2 ' represents hydrogen, lower alkyl with 1 to 4 carbon atoms or diphenylmethyl, CONR 3 'R 4 ', whereby R 3 ' represents hydrogen or methyl and R 4 ' represents hydrogen or alkyl or R 3 ' and R 4 ' form together with the nitrogen a 3- to 6- membered ring or a morpholinyl ring, CH 2 OH, COR 5 ', whereby R 5 ' represents hydrogen or lower alkyl with 1 to 4 carbon atoms, vinyl optionally substituted by CN, Br or lower alkyl with 1 to 4 carbon atoms, alkyl optionally substituted by azido, amino, hydroxy, chloro or alkoxy, tetrazolyl, cyclopropyl, CSNH 2 or -C ⁇ CH.
- C is a N-methyltryptophan residue of formula VI, wherein R 8 represents hydrogen, (C 1 to C 4 )alkoxy, especially methoxy, or alkyl and R 9 represents hydrogen or halogen.
- X is an ⁇ -amino-substituted (C 4 to C 8 ) carboxylic acid residue, which is optionally ⁇ - or ⁇ -(C 1 to C 4 ) alkyl substituted. Most preferably X is an ⁇ -amino- ⁇ - or ⁇ - (C 1 to C 4 ) alkyl-, especially methyl-, substituted octanoic or a butyric acid residue.
- Y is an N-methyl- ⁇ -amino-substituted (C 2 to C 4 ) carboxylic acid residue, which is optionally ⁇ - or ⁇ - ⁇ C 1 to C 4 ) alkyl- substituted. Most preferably Y is an N-methyl- alanine or N-methyl-valine residue.
- the compounds of formula I comprise asymmetric C-atoms and these may be in either the R or S configuration.
- the invention includes open chain peptides or peptolides corresponding to the compounds of formula I; for instance, the open chain molecules obtained by either cleavage of the ester bond between residues Y and A or cleavage of an amide linkage between any other adjacent pair of the acid residues.
- Preferred open-chain derivatives are compounds of formulae IV and V
- R 7 represents hydrogen or alkyl
- a preferred subgroup of compounds of the invention is the compounds of formula Ip
- B p is an ⁇ -amino- ⁇ -methyl-substituted octanoic acid residue
- R 1p is hydrogen or methyl
- C p is a tryptophan or N-methyl-tryptophan residue, which is optionally N'-(C 1 to C 4 ) alkoxy substituted;
- X p is an ⁇ -amino-substituted (C 2 to C 14 ) carboxylic acid residue
- Y p is an ⁇ -amino- or N-methyl- ⁇ -amino substituted (C 2 to C 10 ) carboxylic acid residue.
- a further subgroup of compounds of the invention are the compounds of formula I'p
- A' p is an ⁇ -hydroxy-substituted butyric acid residue optionally ⁇ -substituted by R' ⁇ , which represents CN, COOR' 2p , CONR' 3p R' 4p , COR' 5p , alkyl, which may be substituted by azido, halogen, alkoxy, optionally protected hydroxy or amino, vinyl, which may be substituted by alkyl, halogen or CN, cycloalkyl, tetrazolyl or -C ⁇ CH, whereby R' 2p represents hydrogen or optionally arylsubstituted alkyl, R' 3p and R' 4p are the same or different and represent hydrogen or alkyl or form together with the nitrogen a 3- to 6-membered ring optionally containing a second heteroatom, and R' 5p represents hydrogen or lower alkyl, B' p is an ⁇ -amino- ⁇ -methyl-substituted octanoic acid residue;
- R' 1p is hydrogen or methyl
- C' p is a tryptophan or N-methyl-tryptophan residue of formula
- R' 8p represents hydrogen, alkoxy, alkyl or benzyl
- R' 9p represents hydrogen or halogen
- R' 10p represents hydrogen or methyl and represents a single or double
- X' p is an ⁇ -amino-substituted (C 2 to C 14 ) carboxylic acid residue
- Y' p is an ⁇ -amino- or N-methyl- ⁇ -amino substituted (C 2 to C 10 ) carboxylic acid residue.
- the invention includes all the compounds of the invention when in salt or ester form as well as in free form.
- the invention includes the strain F92-4471/08 (NRRL 21123) in isolated form and mutants and derivatives thereof as well as all novel cyclopeptolides which are produced by this strain.
- the compounds A and B and related compounds may be obtained by cultivating F92-
- the compounds of the invention may be prepared also by chemical synthesis; for example, using conventional peptide synthesis techniques.
- the final step in the preparation of the compounds is a cyciisation step in which a linear peptide or peptolide comprising the acid residues A, B, R 1 Leu, Leu, C, X and Y linked together in appropriate order is cyclised by an amide- or ester-bond forming reaction.
- the invention includes a process for the preparation of a cyclic peptolide of formula I comprising cyciisation of a linear peptide or peptolide comprising the acid residues A, B, R 1 Leu, Leu, C, X and Y linked together in appropriate order.
- the compounds of the invention exhibit pharmacological activity and are therefore useful as pharmaceuticals.
- the compounds are inhibitors of the stimulated expression of cellular adhesion molecules, especially inhibitors of VCAM-1 relative to E- selectin and ICAM-1 expression.
- the effect on VCAM-1 inhibition occurs at both transcriptional and posttranscriptional level.
- Assays which may be used to detect the inhibition of ICAM-1, VCAM-1 and E-selectin expression by the compounds of the invention are described after the Examples.
- the compounds are useful for the treatment or prophylaxis of disease processes which involve expression of cellular adhesion molecules. These disease processes include many acquired and inherited diseases/disorders where leucocyte trafficing plays a prominent role in the pathogenic process, most notably acute and chronic inflammation (e.g.
- the compounds of the invention include tumour metastasis (e.g. melanoma, osteocarcinoma) and allograft/xenograft rejection, since it is known that inhibition of vascular adhesion molecules can greatly improve the prognosis of these processes.
- tumour metastasis e.g. melanoma, osteocarcinoma
- allograft/xenograft rejection since it is known that inhibition of vascular adhesion molecules can greatly improve the prognosis of these processes.
- the compounds of the invention have therapeutic potential in hyperproliterative skin diseases (e.g. psoriasis) as well as various malignancies in view of their inhibitory activity at submicromolar concentrations when tested for 72 hours in a keratinocyte- based as well as other proliferation assays.
- the compounds of the invention are active in inhibiting TNF ⁇ - or IL6-induced HIV production in the U1 monocytic cell line, as evaluated by p24 Elisa and are therefore also useful in the treatment of immunodeficiences and virally caused diseases, especially in the treatment of AIDS.
- the invention also includes the therapeutic use of, and therapeutic compositions containing, the compounds of the invention.
- the invention includes methods for the treatment or prophylaxis of diseases which involve expression of adhesion molecules which comprise administering a therapeutically or prophylactically effective amount of a compound according to the invention to a subject.
- the invention also includes therapeutic compositions comprising a therapeutically effective amount of a compound according to the invention.
- compositions may be for parenteral, oral, aerosol or topical use and usually comprise one or more pharmaceutically acceptable carriers diluents or excipients and may comprise additives such as stabilisers and the like.
- the dosages of the compounds used may be varied having regard to the condition or disease involved, whether the use is for treatment or prophylaxis thereof and the mode and route of administration among other things. In general, however satisfactory results are obtained on administration orally at dosages of from about 0.05 to about 10mg/kg/day, preferably from about 0.1 to about 7.5mg/kg/day, more preferably from about 0.1 to about 2 mg/kg/day administered once or, in divided doses, 2 to 4 times per day.
- parenteral administration e.g.
- dosages from about 0.01 to about 5 mg/kg/day, preferably from about 0.05 to about 1 mg/kg/day and more preferably from about 0.1 to about 1.0mg/kg/day may be used.
- Suitable daily dosages for human patients are thus from about 2.5 to about 500 mg p.o., preferably from about 5 to about 250 mg p.o., more preferably from about 5 to about 100 mg p.o.; or from about 0.5 to about 250 mg i.v., preferably from about 2.5 to about 125 mg i.v. and more preferably from about 2.5 to about 50 mg i.v..
- the compounds may be administered by any appropriate route, including enterally, parenterally and topically or by inhaler.
- Suitable enterally administered forms are solutions for drinking, tablets or capsules.
- Suitable parenteral forms are injectable solutions or suspensions.
- Suitable forms for topical administration include creams, lotions and the like at a concentration range of 0.01-10%, preferably from 0.1 to 1 %, by weight for such formulations.
- Suitable unit dosage forms for oral administration may comprise from 1 to 50 mg of the compound, usually from 1 to 10 mg.
- the compound of example 4 in the preferred compound of the invention and may be administered to larger mammals, for example humans, by similar modes of administration at similar or lower dosages than conventionally employed with known standards for such indications.
- Figure 1 shows the UV spectra of compounds A (a) and B (b);
- Figure 2 shows the IR spectrum of compound A
- Figure 3 shows the IR spectrum of compound B
- Figure 4 shows the proton NMR spectrum of compound A
- Figure 5 shows the proton NMR spectrum of compound B
- Figure 6 shows the 13 C NMR spectrum of compound A
- Figure 7 shows the 13 C NMR spectrum of compound B.
- nPr n-propyl
- Hba modified 2-hydroxybutyric acid
- the fungal strain NRRL 21123 which produces compounds A and B was isolated from a leaf litter sample collected near La Plata, Argentina.
- the strain NRRL 21123 When grown on a 2% malt agar Medium A (2% malt extract, 0,4 % yeast extract, 2% agar in deionised water) the strain NRRL 21123 produces after three days of incubation at 27° colonies of 25 to 35 mm diameter. Colonies usually develop a short aerial mycelium which is white to grey or greyish-brown.
- the optimal temperature for growth is between 21 ° and 30°
- the minimal temperature is between 0° and 6°
- maximal temperature is between 33° and 38°.
- Sporulation was observed after four days incubation in a range between 21 ° and 33°.
- the fungal strain NRRL 21123 produces hyaline to very light brown conidia on phialidic or annelidic conidiogenous cells, within well defined pycnidia.
- the conidia are generally five-celled, cylindrical, usually slightly curved and the majority measure 24-26 x 2,6-4 urn. Each conidium bears at one end a single hyaline unbranched appendage and at the other terminal cell two to four (usually three) hyaline and unbranched appendages.
- strain NRRL 21123 can be accomodated within the genus Bartalinia Tassi.
- the strain NRRL 21123 is grown for 15 days at 21° on an agar slant containing Medium A (2% malt extract, 0,4 % yeast extract, 2% agar, deionized water). The conidia of one slant are suspended in 10 ml sterile tap water. 1 ml conidial suspension is inoculated into each of two 500 ml Erlenmeyer flasks containing 200 ml Medium B (2 % malt extract, 0.4% yeast extract in deionised water). These flasks are incubated for 6 days at 21 ° on a rotary shaker at a speed of 200 RPM to produce the preculture.
- Medium A 2% malt extract, 0,4 % yeast extract, 2% agar, deionized water.
- the conidia of one slant are suspended in 10 ml sterile tap water. 1 ml conidial suspension is inoculated into each of two 500 ml Erlenmeyer flasks containing 200 ml
- a cold solution of HCl in ether (30 ml, 17% w/v, -20°) is added to a mixture of 2 g of compound A and 1.65 ml of methanol and is kept at -20° for 3 days.
- the reaction mixture is then poured onto aqueous bicarbonate solution and extracted with ethyl acetate.
- the organic extract is dried over sodium sulfate, filtered and evaporated in vacuo.
- the crude product is dissolved in 30 ml of methanol/conc. aqueous HCl (9/1) and stirred at room temperature for 3 h.
- the solution is then diluted with water and extracted with ethyl acetate.
- the organic extract is dried over sodium sulfate, filtered and evaporated in vacuo.
- a solution of 10 mg of the compound of example 5 in 0.5 ml of dichloromethane is cooled to 0° and 50 ⁇ l of thionyl chloride are added.
- the reaction mixture is kept at 0° for 1.5 h and then evaporated at 0° in vacuo.
- the remaining yellow oil is dissolved in 1 ml of dichloromethane at 0° and 100 ⁇ l of a 40% aqueous methylamine solution are added. After 45 min the reaction mixture is poured onto 0.1 M aqueous HCl, extracted with ethyl acetate and partitioned between ethyl acetate and sat. aqueous bicarbonate solution.
- the organic phase is washed with brine, dried over sodium sulfate and evaporated in vacuo.
- a solution of 20 mg of the compound of example 18 in 1 ml of dry dimethylformamide is mixed with 1 ml of iodomethane and a solution of 5 mg of sodium bis(trimethylsilyl)amide in 0.3 ml of dimethylformamide is added.
- the mixture is poured onto 0.1 M aqueous HCl, extracted with ethyl acetate and partitioned between ethyl acetate and saturated aqueous bicarbonate solution.
- the organic phase is washed with brine, dried over sodium sulfate and evaporated in vacuo.
- a heterogenous mixture of 25 mg of the compound of example 18, 1 ml of trifluoroacetic acid and 0.3 ml of triethylsilane is vigorously stirred under argon atmosphere at 4° for 20 h.
- the reaction mixture is poured onto saturated aqueous bicarbonate solution and extracted with ethyl acetate.
- the organic phase is washed with brine, dried over sodium sulfate and evaporated in vacuo.
- N-hydroxy indole intermediate are evaporated, the residue is taken up in 2 ml of dry DMF, 2 ml of propyl iodide and 7.5 mg of sodium bis(trimethylsilyl)amide are added.
- the activities of the compounds of the invention are tested in assays for cytotoxicity and inhibition of ICAM-1 , VCAM-1 and E-selectin expression, as well as cell proliferation.
- concentrations of compound required for half-maximal inhibition (IC 50 ) in each assay are given in Table 2 below.
- the assays were carried out as follows:
- HaCaT cells a spontaneously-transformed, non-tumorigenic human keratinocyte cell line with highly preserved phenotypic differentiation characteristics of normal keratinocytes (Boukamp et al., 1988 J. Cell Biol. 106, 761-771), are used both for the cell proliferation assay and the ICAM-1 cell Eiisa.
- the ICAM-1 cell Elisa used to determine inhibition of ICAM-1 expression is substantially as described by Winiski and Foster (1992, J. Invest. Dermatol., 99, 48-52).
- HaCaT cells are seeded in 96 well microtiter plates (2x10 4 cells/well in culture medium: DMEM with 5% FCS, 100 U/ml Penicillin, 100 ⁇ g/ml Streptomycin, 2mM Glutamine, 1 mM Na Pyruvate), grown to confluency, and then incubated in fresh test medium (as for culture medium but with 0.5% FCS instead of 5%) with or without IFN- ⁇ /TNF- ⁇ stimulation medium (test medium + 1000 U/ml IFN- ⁇ / 3ng/ml TNF- ⁇ ) both in the presence and absence of compound A or compound B for ca.
- the medium is then washed away and the cell monolayers are fixed with 1 % parafomraldehyde.
- the monolayers are incubated with saturating amounts of primary (mouse anti-ICAM-1 monoclonal) and secondary (goat anti-mouse peroxidase conjugated) antibodies.
- the subsequent peroxidase reaction uses 3-amino-9-ethylcarbazole (AEC) as substrate and generates an insoluble, colored product, which is easily measured in a standard microtiter plate reader.
- AEC 3-amino-9-ethylcarbazole
- the HaCaT monolayers are rinsed with PBS (200 ⁇ L), the PBS is poured off from the plates which are then patted dry on top of a paper towel to remove excess liquid. The bottom surfaces of the microtitre plates are gently wiped with a moist facial tissue and then again with a dry facial tissue and absorbance read at 492nm. Before the monolayers can dry out 0.1 ml of 0.1% crystal violet solution in PBS (passed first through a 0.2 ⁇ m filter) is added to each well.
- VCAM-1 Endothellal cell VCAM-1. ICAM-1 and E-selectin Cell-Elisa Assay The assay is based on a 96-well cell Elisa method using the human microvascular endothelial cell line HMEC-1 and human umbilical vein endothelial cells (HUVEC). Cells are pretreated for four hours with test compound A or compound B, stimulated for the next 8-16 hours with TNF ⁇ , then parafomaldehyde-fixed for subsequent evaluation of VCAM-1, ICAM-1 or E-selectin expression by an indirect immunoperoxidase staining technique.
- Cytotoxic effects are determined by counting the relative number of cells (Giemsa nuclear stain) after exposure to the test substances, in comparison to the control wells (solvent and media only). Compounds are scored positive if they exhibit ⁇ 50% VCAM-1 , ICAM-1 or E-selectin inhibition with ⁇ 25% cell loss.
- HMEC-1 human microvascular endothelial cell line
- HMEC-1 cells constitutively express low levels of ICAM-1 which are upregulated by inflammatory mediators. However, they only express VCAM-1 following cytokine stimulation. Dose-response and time-course experiments were performed to determine the optimal conditions for inducing VCAM-1 and ICAM-1 expression.
- Basal Medium [EBM; Clonetics] supplemented with 10% FCS, 10 ng/ml human EGF (Boehringer), 1 ⁇ g/ml hydrocortisone (Sigma # 0888), 2.2 g/l NaHCO 3 , 15 mM Hepes, 0.11 g/l sodium pyruvate, 4 mM glutamine, 100 U/ml penicillin and 100 ⁇ g/ml streptomycin). After mild trypsinization (0.25% trypsin + 0.1% EDTA for 8 min) and resuspension, the cells are reseeded every 2-3 days at a 1:3 splitting ratio.
- 96 well flat-bottom microtiter plates are precoated with bovine fibronectin (FN; Sigma # F1141) and then seeded with 2 x 10 4 cells/well in 200 ⁇ l of EBM growth medium and incubated overnight.
- CM culture medium
- CM supplemented with 5% FCS instead of 10% the culture medium
- Each 96-well assay is performed with duplicate wells.
- the cells are then stimulated by adding 20 ⁇ l of concentrated cytokine solution (2000 U/ml TNF ⁇ ) and incubated for 16 hr at 37° C.
- the cell monolayer is then washed with 1 % paraformaldehyde in EBM medium, fixed in 2% parafomaldehyde for 15 min at room temperature (RT) and rinsed several times with PBS.
- the PBS is removed from the cells, and the monolayer is incubated for 30 min in PBS containing 10% normal goat serum (NGS).
- NGS normal goat serum
- the NGS solution is replaced with 100 ⁇ l/well of the anti- VCAM-1 or ICAM-1 monoclonal antibody and incubated overnight at 4° C.
- the mAb solution is then removed and the cells rinsed several times with PBS, followed by incubation with PBS containing 10% NGS for 30-60 min at RT.
- the NGS solution is removed and 100 ⁇ l of horseradish peroxidase-conjugated goat F(Ab') 2 anti- mouse IgG antibody (Tago; 1.500 dilution in PBS containing 5% NGS) is added and the plates incubated for 1 hr at RT.
- the secondary antibody is then removed and the cells rinsed in PBS, which is then replaced with 150 ⁇ l/well of a freshly-prepared and filtered AEC solution (3-amino-9ethyl-carbazole; Sigma) and the plates incubated for 45-60 min at RT.
- the peroxidase substrate is removed and the cells rinsed in PBS.
- AEC absorbance values are read on a microtiter plate reader at 550 nm and corrected for "blank" or reference values at 690 nm.
- E-selectin assay The E-selectin assay is performed using freshly isolated HUVEC, essentially as described for the VCAM-1 or ICAM-1 assay except for a shorter TNF ⁇ - stimulation (6-8 hours).
- the endothelial cells are destained by replacing the PBS with 95% ethanol for 20 min (two 10 min changes) with control by microscopic evaluation.
- the cells are then rinsed in distilled water (Aquadest) and the monolayer covered with a 33% Giemsa solution in Aquadest for 5 min at RT.
- the wells are then washed with Aquadest and air dry for at least 15 min.
- Microscopic evaluation is used to check that only the nuclei are stained, with essentailly no cytoplasmic staining. Giemsa absorbance values are read on a microtiter plate reader at 550 nm and corrected for "blank" values (rows without cells) at 690 nm.
- AEC-CAM E-selectin Cell adhesion molecule
- AEC-CAM / Giemsa AEC:Giemsa ratio
- CAM IC50 values are determined by comparing the AEC:Giemsa values for a test substance with those of the stimulated control (EBM, solvent). These values are then analyzed relative to the IC50 values for Giemsa alone. Strict criteria determine whether the CAM inhibition versus cytotoxicity (Giemsa) profile indicates a
- HaCaT cells are cultivated in DMEM (Gibco # 074-02100) supplemented with 2.2 g/l NaHCO 3 , 0.11 g/l sodium pyruvate, 15 mM Hepes, 5% fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 ⁇ g/ml), and glutamine (to increase the final concentration by 4 mM).
- DMEM Gibco # 074-02100
- FCS fetal calf serum
- penicillin 100 U/ml
- streptomycin 100 ⁇ g/ml
- glutamine glutamine
- the extent of cellular proliferation in comparison to solvent controls is measured by a colorimetric assay that measures relative cell mass using the dye sulforhodamine B (Skehan et al, 1990, J. Natl. Cancer Inst. 82, 1107-1112).
- a dose-response curve is plotted semi-logarithmically and the concentration required for half-maximal inhibition (IC 50 ) is determined by linear interpolation. Maximal inhibition without net loss of cells is represented by the "starting cell number" and is usually between 90-98%.
- MeMeOTrp H-ßb 3.20°(s, N-Me); 3.17*(s, N-Me); 2.93* (s, MeMeOTrp N-Me); 2.54* (s, MeLeu N-Me); 2.53° (s, N-Me); 2.4-2.35 (m); 2.2-1.9 (m); 1.83-1.05 (m); 1.53*.
- PrLeu NH 7.49* (d, 7Hz, indole H-4'); 7.48° (d, 7Hz, indole H-4'); 7.43* (d, 8Hz, indole H-T); 7.41 ° (d, 8Hz, indole H-7'); 7.27* (dd, indole H-6'); 7.23° (dd, indole H-6'); 7.13* (dd, indole H-5'); 7.08° (dd, indole H-5'); 7.04° (s, indole H-2'); 7.02* (s, indole H-2'); 6.98' (s, indole H-2'); 6.2° (d, 10Hz, Leu NH); 6.01* (d, 7Hz, Leu NH); 5.79' (d, 9Hz, Leu NH); 5.30° (ddd, PrLeu6 ⁇ -H); 5.07* (dd, Hba ⁇ -H); 5.03* (
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50548596A JP3425763B2 (en) | 1994-07-27 | 1995-07-26 | Organic compounds |
AU32221/95A AU702332B2 (en) | 1994-07-27 | 1995-07-26 | Organic compounds |
SI9530367T SI0775158T1 (en) | 1994-07-27 | 1995-07-26 | Cyclopeptolides |
DE69513837T DE69513837T2 (en) | 1994-07-27 | 1995-07-26 | Cyclopeptolides |
SK117-97A SK11797A3 (en) | 1994-07-27 | 1995-07-26 | Cyclopeptolides, process for their preparation and their use in therapy |
EP95928473A EP0775158B1 (en) | 1994-07-27 | 1995-07-26 | Cyclopeptolides |
CA002192786A CA2192786C (en) | 1994-07-27 | 1995-07-26 | Cyclopeptolide inhibitors of adhesion molecules |
NZ291168A NZ291168A (en) | 1994-07-27 | 1995-07-26 | Cyclopeptolides which inhibit expression of adhesion molecules (icam-1, vcam and e-selectin) |
US08/776,440 US6013627A (en) | 1994-07-27 | 1995-07-26 | Organic compounds |
BR9508342A BR9508342A (en) | 1994-07-27 | 1995-07-26 | Organic compounds |
MX9606494A MX9606494A (en) | 1994-07-27 | 1995-07-26 | Organic compounds. |
DK95928473T DK0775158T3 (en) | 1994-07-27 | 1995-07-26 | cyclopeptolides |
PL95317349A PL181990B1 (en) | 1994-07-27 | 1995-07-26 | Organic compounds |
FI970279A FI970279A (en) | 1994-07-27 | 1997-01-23 | Organic compounds |
NO970340A NO970340D0 (en) | 1994-07-27 | 1997-01-27 | Organic compounds |
HK98115157A HK1014011A1 (en) | 1994-07-27 | 1998-12-23 | Cyclopeptolides |
GR20000400396T GR3032698T3 (en) | 1994-07-27 | 2000-02-18 | Organic compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9415168.5 | 1994-07-27 | ||
GB9415168A GB9415168D0 (en) | 1994-07-27 | 1994-07-27 | Organic compounds |
GBGB9504332.9A GB9504332D0 (en) | 1995-03-03 | 1995-03-03 | Organic compounds |
GB9504332.9 | 1995-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996003430A1 true WO1996003430A1 (en) | 1996-02-08 |
Family
ID=26305345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/002966 WO1996003430A1 (en) | 1994-07-27 | 1995-07-26 | Organic compounds |
Country Status (26)
Country | Link |
---|---|
US (1) | US6013627A (en) |
EP (1) | EP0775158B1 (en) |
JP (1) | JP3425763B2 (en) |
KR (1) | KR100378974B1 (en) |
CN (1) | CN1116304C (en) |
AT (1) | ATE187461T1 (en) |
AU (1) | AU702332B2 (en) |
BR (1) | BR9508342A (en) |
CA (1) | CA2192786C (en) |
CY (1) | CY2225B1 (en) |
CZ (1) | CZ289311B6 (en) |
DE (1) | DE69513837T2 (en) |
DK (1) | DK0775158T3 (en) |
ES (1) | ES2142490T3 (en) |
FI (1) | FI970279A (en) |
GR (1) | GR3032698T3 (en) |
HK (1) | HK1014011A1 (en) |
HU (1) | HUT77388A (en) |
MX (1) | MX9606494A (en) |
NO (1) | NO970340D0 (en) |
NZ (1) | NZ291168A (en) |
PL (1) | PL181990B1 (en) |
PT (1) | PT775158E (en) |
RU (1) | RU2155772C2 (en) |
SK (1) | SK11797A3 (en) |
WO (1) | WO1996003430A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997019104A1 (en) * | 1995-11-21 | 1997-05-29 | Novartis Ag | Cyclopeptolides |
WO1999014082A1 (en) | 1996-09-18 | 1999-03-25 | Minnesota Mining And Manufacturing Company | Adhesively-bonded inflatable restraint and method of making |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
WO2002034283A2 (en) * | 2000-10-27 | 2002-05-02 | Novartis Ag | Vegh inhibitors and their use |
WO2002042294A1 (en) * | 2000-11-21 | 2002-05-30 | Celltech R & D Limited | 1-sulfonyl substituted tryptophane derivatives and its use as integrin inhibitors |
WO2002057778A1 (en) * | 2001-01-22 | 2002-07-25 | Novartis Ag | Screening assay for cotranslational translocation interfering compounds |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
EP3663405A1 (en) | 2013-06-11 | 2020-06-10 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU783158B2 (en) * | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4443367A (en) * | 1982-04-08 | 1984-04-17 | Monsanto Company | Peptide and peptolide substrates for mammalian collagenase |
EP0360370A2 (en) * | 1988-09-21 | 1990-03-28 | Howaldtswerke-Deutsche Werft Ag | Depth-controlled ejection valve mechanism |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4425428A (en) * | 1982-04-08 | 1984-01-10 | Monsanto Company | Novel peptide and peptolide substrates for mammalian collagenase |
ES2056954T3 (en) * | 1987-06-19 | 1994-10-16 | Sandoz Ag | CYCLIC PEPTOLIDS. |
DE3832362A1 (en) * | 1988-09-23 | 1990-03-29 | Sandoz Ag | NEW CYCLOPEPTOLIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
-
1995
- 1995-07-26 RU RU97102700/04A patent/RU2155772C2/en not_active IP Right Cessation
- 1995-07-26 DE DE69513837T patent/DE69513837T2/en not_active Expired - Fee Related
- 1995-07-26 AU AU32221/95A patent/AU702332B2/en not_active Ceased
- 1995-07-26 PT PT95928473T patent/PT775158E/en unknown
- 1995-07-26 JP JP50548596A patent/JP3425763B2/en not_active Expired - Fee Related
- 1995-07-26 AT AT95928473T patent/ATE187461T1/en not_active IP Right Cessation
- 1995-07-26 WO PCT/EP1995/002966 patent/WO1996003430A1/en active IP Right Grant
- 1995-07-26 MX MX9606494A patent/MX9606494A/en not_active IP Right Cessation
- 1995-07-26 US US08/776,440 patent/US6013627A/en not_active Expired - Fee Related
- 1995-07-26 DK DK95928473T patent/DK0775158T3/en active
- 1995-07-26 CA CA002192786A patent/CA2192786C/en not_active Expired - Fee Related
- 1995-07-26 BR BR9508342A patent/BR9508342A/en not_active Application Discontinuation
- 1995-07-26 PL PL95317349A patent/PL181990B1/en unknown
- 1995-07-26 SK SK117-97A patent/SK11797A3/en unknown
- 1995-07-26 KR KR1019970700504A patent/KR100378974B1/en not_active IP Right Cessation
- 1995-07-26 HU HU9700226A patent/HUT77388A/en unknown
- 1995-07-26 EP EP95928473A patent/EP0775158B1/en not_active Expired - Lifetime
- 1995-07-26 ES ES95928473T patent/ES2142490T3/en not_active Expired - Lifetime
- 1995-07-26 CZ CZ1997221A patent/CZ289311B6/en not_active IP Right Cessation
- 1995-07-26 NZ NZ291168A patent/NZ291168A/en unknown
- 1995-07-26 CN CN95194370A patent/CN1116304C/en not_active Expired - Fee Related
-
1997
- 1997-01-23 FI FI970279A patent/FI970279A/en unknown
- 1997-01-27 NO NO970340A patent/NO970340D0/en unknown
-
1998
- 1998-12-23 HK HK98115157A patent/HK1014011A1/en unknown
-
2000
- 2000-02-18 GR GR20000400396T patent/GR3032698T3/en unknown
-
2001
- 2001-06-08 CY CY0100011A patent/CY2225B1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4443367A (en) * | 1982-04-08 | 1984-04-17 | Monsanto Company | Peptide and peptolide substrates for mammalian collagenase |
EP0360370A2 (en) * | 1988-09-21 | 1990-03-28 | Howaldtswerke-Deutsche Werft Ag | Depth-controlled ejection valve mechanism |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
WO1997019104A1 (en) * | 1995-11-21 | 1997-05-29 | Novartis Ag | Cyclopeptolides |
US6011136A (en) * | 1995-11-21 | 2000-01-04 | Novartis Ag | Cyclopeptolides |
WO1999014082A1 (en) | 1996-09-18 | 1999-03-25 | Minnesota Mining And Manufacturing Company | Adhesively-bonded inflatable restraint and method of making |
US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
WO2002034283A2 (en) * | 2000-10-27 | 2002-05-02 | Novartis Ag | Vegh inhibitors and their use |
WO2002034283A3 (en) * | 2000-10-27 | 2003-02-13 | Novartis Ag | Vegh inhibitors and their use |
WO2002042294A1 (en) * | 2000-11-21 | 2002-05-30 | Celltech R & D Limited | 1-sulfonyl substituted tryptophane derivatives and its use as integrin inhibitors |
WO2002057778A1 (en) * | 2001-01-22 | 2002-07-25 | Novartis Ag | Screening assay for cotranslational translocation interfering compounds |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
EP3663405A1 (en) | 2013-06-11 | 2020-06-10 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
FI970279A0 (en) | 1997-01-23 |
CN1154705A (en) | 1997-07-16 |
CA2192786A1 (en) | 1996-02-08 |
CN1116304C (en) | 2003-07-30 |
KR100378974B1 (en) | 2003-10-08 |
HUT77388A (en) | 1998-04-28 |
AU3222195A (en) | 1996-02-22 |
CZ22197A3 (en) | 1997-05-14 |
MX9606494A (en) | 1997-03-29 |
CY2225B1 (en) | 2003-04-18 |
DK0775158T3 (en) | 2000-05-22 |
CA2192786C (en) | 2009-06-16 |
RU2155772C2 (en) | 2000-09-10 |
DE69513837T2 (en) | 2000-05-18 |
FI970279A (en) | 1997-01-23 |
SK11797A3 (en) | 1997-07-09 |
US6013627A (en) | 2000-01-11 |
PT775158E (en) | 2000-05-31 |
NO970340L (en) | 1997-01-27 |
NO970340D0 (en) | 1997-01-27 |
ATE187461T1 (en) | 1999-12-15 |
NZ291168A (en) | 1998-06-26 |
PL181990B1 (en) | 2001-10-31 |
ES2142490T3 (en) | 2000-04-16 |
DE69513837D1 (en) | 2000-01-13 |
AU702332B2 (en) | 1999-02-18 |
CZ289311B6 (en) | 2001-12-12 |
HK1014011A1 (en) | 1999-09-17 |
BR9508342A (en) | 1997-10-21 |
EP0775158B1 (en) | 1999-12-08 |
EP0775158A1 (en) | 1997-05-28 |
JPH10504540A (en) | 1998-05-06 |
JP3425763B2 (en) | 2003-07-14 |
GR3032698T3 (en) | 2000-06-30 |
PL317349A1 (en) | 1997-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100203556B1 (en) | Novel cyclosporins | |
CA1335083C (en) | Fr901228 substance and preparation thereof | |
JP2641256B2 (en) | Cyclic peptides | |
EP0775158B1 (en) | Cyclopeptolides | |
US5643869A (en) | Pipecolic acid-containing peptolides, their preparation and pharmaceutical compositions containing them | |
KR100997073B1 (en) | Memno peptides, a process for their preparation and a pharmaceutical composition comprising the same | |
US5789602A (en) | Physiologically active substances PF1092A, PF1092B and PF1092C, process for the production thereof, and contraceptives and anticancer drugs containing the same as active ingredients | |
WO1995006649A1 (en) | Macrolides as antagonists of macrophilin binding immunosuppressants | |
AU712900B2 (en) | Cyclopeptolides | |
CA2224025A1 (en) | Novel antibiotic, feglymycin, processes for its preparation and its use | |
MXPA01010245A (en) | Pseudomycin natural products. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194370.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 291168 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995928473 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2192786 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-221 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11797 Country of ref document: SK Ref document number: 08776440 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970700504 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-221 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995928473 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970700504 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995928473 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-221 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970700504 Country of ref document: KR |